This risk of serious infections in obese vs nonobese patients was similar in several strata, including disease phenotype (CD and UC), age (≤60 and >60 years), type of biologic exposure (TNFα antagonists and vedolizumab), and in patients with or without major comorbidities (Table 2). The gene discussed is TNF; the disease is infection.